It’s the stock of a tiny, little-known pharmaceutical company, trading for less than $50 a share. This company controls a potential cure for the obesity epidemic.
Dave has done the research, dating back four years. He’s one of a handful of people outside this company’s headquarters who are aware of what’s going on and the nuances of this drug’s development, approval process, and why the company has been so secretive about it.
This drug turns down our natural “hunger switch.” It essentially gives you a higher metabolism. It’s a potentially world-changing drug, and it’s completely under the radar… but won’t be for much longer.

This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.